Cephalexin Shortage: A Provider's Perspective for 2026

As a prescriber, few things are as frustrating as writing a prescription you know is right for the patient — only to have them call back because the pharmacy can't fill it. Cephalexin, one of the most reliable and cost-effective antibiotics in our toolkit, has been subject to intermittent supply disruptions since the antibiotic shortage wave that began in late 2022.

This guide provides a clinical overview of the current Cephalexin supply situation, evidence-based therapeutic alternatives, and practical strategies to help your patients get the treatment they need.

Current Supply Status

As of early 2026, the Cephalexin supply picture varies by formulation:

• Oral capsules (250 mg, 500 mg): Generally available. Isolated supply gaps may occur but are not widespread.
• Oral tablets (250 mg, 500 mg): Similarly available with occasional interruptions.
• Oral suspension (125 mg/5 mL, 250 mg/5 mL): Continues to experience the most significant supply constraints. Pediatric patients requiring liquid formulations remain the most affected population.

Providers should monitor the ASHP Drug Shortages Resource Center and the FDA Drug Shortages Database for real-time updates.

Understanding the Supply Chain Vulnerabilities

The Cephalexin shortage reflects broader systemic issues in generic antibiotic manufacturing:

Limited API Manufacturing

Analysis of the global pharmaceutical supply chain reveals approximately 39 API manufacturing sites capable of producing cephalexin — a relatively low number for such a widely prescribed medication. For comparison, azithromycin has approximately 81 API manufacturing sites. This concentration creates single-point-of-failure risk.

Economic Disincentives

Generic cephalexin typically retails for under $15 with discount coupons. At these price points, manufacturers face thin margins that disincentivize capacity expansion and inventory buffering. The economic model of generic antibiotic manufacturing has been well-documented as a contributor to shortage risk.

Demand Volatility

Antibiotic prescribing is inherently seasonal. During peak respiratory illness seasons, oral antibiotic prescriptions can increase 30-50%, creating demand surges that outstrip just-in-time manufacturing capacity. The unprecedented respiratory season of 2022-2023 exposed these vulnerabilities in dramatic fashion.

Clinical Considerations for Alternative Therapy

When Cephalexin is unavailable, the appropriate alternative depends on the indication, patient allergy history, local resistance patterns, and available formulations.

Skin and Soft Tissue Infections (SSTIs)

First-line alternatives:

• Cefadroxil 500 mg BID — Same generation, same spectrum. Longer half-life allows twice-daily dosing, which may improve adherence. Check local availability.
• Dicloxacillin 500 mg QID — Narrow-spectrum anti-staphylococcal coverage. Suitable for uncomplicated SSTIs when MSSA is suspected.

Second-line alternatives:

• Trimethoprim-sulfamethoxazole (TMP-SMX) DS BID — Provides MRSA coverage. Consider for purulent SSTIs or in communities with high MRSA prevalence.
• Doxycycline 100 mg BID — MRSA-active. Good option for adults with beta-lactam allergy.
• Clindamycin 300-450 mg TID-QID — Covers MSSA and community-associated MRSA. Monitor for C. difficile risk.

Urinary Tract Infections (UTIs)

First-line alternatives:

• Nitrofurantoin 100 mg BID x 5 days — IDSA-recommended first-line for uncomplicated cystitis. Not appropriate for pyelonephritis or CrCl <30 mL/min.
• TMP-SMX DS BID x 3 days — Effective when local resistance rates are <20%.

Second-line alternatives:

• Fosfomycin 3 g single dose — Convenient single-dose option for uncomplicated cystitis.
• Amoxicillin-clavulanate 500/125 mg TID — When broader coverage is needed.

Streptococcal Pharyngitis

First-line alternatives:

• Amoxicillin 500 mg BID or 1000 mg daily x 10 days — IDSA first-line recommendation. Preferred for adherence with once or twice daily dosing.
• Penicillin V 500 mg BID-TID x 10 days — The classic choice.

For penicillin-allergic patients:

• Azithromycin 500 mg day 1, then 250 mg days 2-5 — Consider local macrolide resistance patterns.
• Clindamycin 300 mg TID x 10 days

Otitis Media

First-line alternatives:

• Amoxicillin 80-90 mg/kg/day divided BID (pediatric) — AAP first-line recommendation.
• Amoxicillin-clavulanate 90 mg/kg/day (amoxicillin component) divided BID — For treatment failure or beta-lactamase concern.

For cephalosporin-allergic patients:

• Azithromycin or Clindamycin based on severity and allergy history.

Surgical Prophylaxis

For patients receiving cephalexin as surgical prophylaxis (e.g., post-cesarean section), consider:

• Cefazolin (IV) — Standard perioperative prophylaxis when IV access is available.
• Amoxicillin-clavulanate — Oral option for outpatient surgical prophylaxis.

Prescribing Strategies During Shortage Periods

Formulation Flexibility

When writing a Cephalexin prescription, consider specifying "may substitute formulation" or sending in multiple formulation options. If the pharmacy is out of 500 mg capsules, they may have 250 mg tablets that can be doubled.

Proactive Communication

Inform patients that supply may be limited and provide guidance on what to do if the pharmacy can't fill their prescription. Consider:

• Prescribing a backup alternative with instructions to fill only if Cephalexin is unavailable.
• Providing a list of pharmacies to check, or directing them to Medfinder for Providers to streamline pharmacy stock searches.

Real-Time Availability Tools

Medfinder allows providers and staff to check pharmacy availability for Cephalexin and other medications in real time, reducing phone-tag with pharmacies and helping patients get their prescriptions filled faster.

Antibiotic Stewardship

Shortages create pressure to use broader-spectrum antibiotics as substitutes. Maintain stewardship principles:

• Use the narrowest effective spectrum.
• Avoid fluoroquinolones for uncomplicated infections when alternatives are available.
• Reserve broader-spectrum agents for documented or high-risk resistant infections.

Patient Communication Guidance

Patients are understandably anxious when they can't get their antibiotic. Consider these talking points:

• "The shortage doesn't mean there's anything wrong with Cephalexin — it's a manufacturing supply issue."
• "We have effective alternatives that will treat your infection just as well."
• "If the pharmacy doesn't have Cephalexin, call us right away — we can switch your prescription quickly."
• "You can use Medfinder to check which pharmacies near you have it in stock."

Direct patients to our patient-facing resources including the Cephalexin shortage update for patients and the guide on how to find Cephalexin in stock.

Looking Ahead

The FDA and Congress have taken steps to address drug shortage vulnerabilities, including proposals for manufacturing quality incentives, strategic stockpiling of essential medicines, and supply chain transparency requirements. While these efforts are promising, the structural issues underlying antibiotic shortages — concentrated manufacturing, thin margins, and demand unpredictability — will take years to fully resolve.

In the meantime, staying informed, maintaining prescribing flexibility, and leveraging tools like Medfinder for Providers can help ensure your patients get the treatment they need without unnecessary delays.

Key Takeaways for Providers

• Cephalexin capsules/tablets are generally available; oral suspension remains intermittently constrained.
• Cefadroxil is the most direct therapeutic equivalent (same generation, same spectrum, better dosing interval).
• Match alternative selection to indication, allergy history, and local resistance patterns.
• Use formulation flexibility and proactive patient communication to minimize disruption.
• Medfinder for Providers offers real-time pharmacy availability to streamline the process.

See also: How to help your patients find Cephalexin in stock and how to help patients save money on Cephalexin.